• First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma
   
• Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs)
   

NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology (JCO), one of the most prestigious oncology journals.

The publication, titled: "Intracranial injection of ex vivo expanded and activated gamma-delta T cells engineered with a MGMT-expressing lentivector in patients with primary glioblastoma," reports results from the first-in-human study of an autologous, genetically modified γδ T cell therapy. The expanded, activated γδ T cells are engineered to be resistant to chemotherapy (DeltEx DRI) and delivered intracranially in combination with standard of care (SOC) temozolomide chemotherapy (TMZ).

The Phase 1 trial is a frequency-escalation study of DeltEx DRI in GBM patients in combination with the SOC Stupp regimen (surgical resection followed by chemoradiation and maintenance chemotherapy). A total of 13 patients were enrolled and treated across three cohorts with subjects in their respective cohorts receiving 1, 3, or up to 6 doses of DeltEx DRI in 28-day cycles during maintenance chemotherapy. Evaluations included the safety and feasibility of repeated intracranial administration during maintenance chemotherapy.

GBM is the most common malignant primary brain tumor in adults and one of the most aggressive and difficult cancers to treat, with overall survival of only ~11 months and a five-year survival of ~5%. Despite overall advances across numerous cancer therapies, survival in GBM has been almost unchanged in more than 20 years with no new drug approvals and only a single device approval. Recurrence is nearly universal with GBM patients facing rapid decline, very limited treatment options, and poor outcomes.

In the Phase 1 study, DeltEx DRI in combination with SOC demonstrated a well-tolerated safety profile with no DLTs, no cytokine release syndrome (CRS), and no immune effector cell-associated neurotoxicity (ICANS) observed. The therapy also showed compelling signals of clinical activity. Across all 13 treated patients, mPFS was 9.9 months, and a 43.5% improvement over the 6.9 months typically reported with SOC alone. The results were most striking in repeat-dose patients (those receiving 3 to 6 doses) where mPFS reached 16.1 months, more than double the SOC benchmark. Overall survival (OS) was equally notable: median OS in repeat-dose patients was 19.5 months, compared to a historical SOC mOS of approximately 14.6 months in this patient population.